Pomalyst (pomalidomide) — United Healthcare
Systemic Light Chain Amyloidosis
Initial criteria
- Diagnosis of systemic light chain amyloidosis
- AND
- Used in combination with dexamethasone
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Pomalyst therapy
Approval duration
12 months